NLA GUIDELINES Bundle (free trial)

Dyslipidemia-II NLA

Official NLA Dyslipidemia Guidelines Appsbrought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512431

Contents of this Issue

Navigation

Page 14 of 37

15 Children and Adolescents Chart 5. Children and Adolescents Recommendations Strength Quality Universal lipid screening of all children, regardless of general health or the presence or absence of ASCVD risk factors, is recommended between 9–11 years of age, with repeat lipid screening at 20 years of age or earlier if dyslipidemia is present. E Low If a child or adolescent patient is screened and has a fasting or non-fasting non-HDL-C level ≥145 mg/dL, then additional follow-up is recommended. Two fasting lipid profiles should be obtained and the results averaged for evaluation of the most appropriate course of action. E Low Children ≥2 years of age with the following characteristics should be screened for dyslipidemia: • One or both biological parents are known to have hypercholesterolemia or are receiving lipid- lowering medications • Have a family history of premature ASCVD in an expanded first degree pedigree (i.e., to include not only parents and siblings, but also aunts, uncles, and grandparents) in men <55 or women <65 years of age • Consideration should also be given to screening for those in whom family history is unknown (e.g., adopted) B Moderate Children should be regularly screened for major risk factors and conditions associated with increased ASCVD risk, but there are no validated methods for risk factor scoring in patients <20 years of age. B Moderate Decisions on target levels during treatment are a matter of clinical judgment, but age-appropriate, percentile-based cutpoints from the 2011 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: National Heart, Lung, and Blood Institute (http://www.nhlbi.nih.gov/health-pro/guidelines/ current/cardiovascular-health-pediatric-guidelines/summary) should be considered as the upper limits for therapeutic atherogenic cholesterol goal ranges for managing children and adolescents: • Non-HDL-C: 144 mg/dL • LDL-C: 129 mg/dL E Low Î Although ASCVD events rarely occur in children, the risk factors and risk behaviors that accelerate development of ASCVD are present in childhood. Î The presence and intensity of risk factors are highly correlated with the extent and severity of atherosclerosis. The combined impact of multiple risk factors is exponentially greater than individual factors alone. Î Furthermore, risk factors measured in childhood and adolescence are better predictors of the severity of atherosclerosis than risk factors measured in young adults.

Articles in this issue

Links on this page

Archives of this issue

view archives of NLA GUIDELINES Bundle (free trial) - Dyslipidemia-II NLA